株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

筋萎縮性側索硬化症 : パイプライン製品の分析

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232799
出版日 ページ情報 英文 455 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.71円で換算しております。
Back to Top
筋萎縮性側索硬化症 : パイプライン製品の分析 Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 455 Pages
概要

筋萎縮性側索硬化症(ALS) は運動ニューロン・システムの最も一般的な変性疾患です。この障害は、その原因となっている病態生理学から名づけられ、筋繊維の萎縮に関する筋萎縮症を伴い、対応する前角細胞が退化するに従い、神経が麻痺していきます。この領域の上位運動ニューロン(UMN)軸索が変質して、繊維星状細胞(神経膠症)に取って代わるため、側索硬化症は脊髄の側柱で見られる変化に関係があります。症候として、呼吸困難、嚥下障害、首の筋力低下で頭が前に垂れる、筋けいれん、遅いか異常な話し方(言葉を不明瞭に発音するなど)といった会話障害、変声、しゃがれ声、体重の減少などが見られます。

当レポートでは、筋萎縮性側索硬化症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

筋萎縮性側索硬化症 概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9305IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 2, 24, 11, 1, 72, 21 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 7 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Amyotrophic Lateral Sclerosis - Overview
  • Amyotrophic Lateral Sclerosis - Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Therapeutics Assessment
  • Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
  • Amyotrophic Lateral Sclerosis - Drug Profiles
  • Amyotrophic Lateral Sclerosis - Dormant Projects
  • Amyotrophic Lateral Sclerosis - Discontinued Products
  • Amyotrophic Lateral Sclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by ApoPharma Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Corestem Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Gemac SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by M3 Biotechnology Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Monosol Rx LLC, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurofx Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SA, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Prevacus Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Reata Pharmaceuticals Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences LLC, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed SL, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Symic Biomedical Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics Inc, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Amyotrophic Lateral Sclerosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Amyotrophic Lateral Sclerosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Amyotrophic Lateral Sclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top